Targacept, Inc. (TRGT)

[surf1944]

8:56AM Targacept announces plans to develop TC-5214 in overactive bladder (TRGT) 4.67 : Co announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder. Based on TC-5214's unique pharmacokinetic profile, an analysis of data from a completed clinical program and findings from additional preclinical studies, the company plans to initiate a Phase 2b study of TC-5214 in the first half of 2013.